Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Bioorg Med Chem Lett. 2024 Nov 15;113:129967. doi: 10.1016/j.bmcl.2024.129967. Epub 2024 Sep 16.
Despite the recent progresses in therapeutic and diagnostic methods, there is still a significantly high rate of mortality among cancer patients. One of the main reasons for the high mortality rate in cancer patients is late diagnosis, which leads to the failure of therapeutic strategies. Therefore, investigation of cancer biology can lead to the introduction of early diagnostic markers in these patients. MicroRNAs (miRNAs) play an important role in regulation of cellular processes associated with tumor progression. Due to the high stability of miRNAs in body fluids, these factors can be considered as the non-invasive tumor markers. Deregulation of miR-382 has been widely reported in different cancers. Therefore, in this review, we investigated the role of miR-382 during tumor development. It has shown that miR-382 has mainly a tumor suppressive, which inhibits the growth of tumor cells through the regulation of signaling pathways, RNA-binding proteins, and transcription factors. Therefore, miR-382 can be suggested as a diagnostic and therapeutic marker in cancer patients.
尽管在治疗和诊断方法方面最近取得了进展，但癌症患者的死亡率仍然很高。癌症患者死亡率高的一个主要原因是诊断较晚，导致治疗策略失败。因此，对癌症生物学的研究可以为这些患者引入早期诊断标志物。微小 RNA（miRNA）在调节与肿瘤进展相关的细胞过程中发挥重要作用。由于 miRNA 在体液中的高度稳定性，这些因素可以被认为是无创的肿瘤标志物。miR-382 的失调已在不同癌症中广泛报道。因此，在本综述中，我们研究了 miR-382 在肿瘤发展过程中的作用。研究表明，miR-382 主要具有肿瘤抑制作用，通过调节信号通路、RNA 结合蛋白和转录因子来抑制肿瘤细胞的生长。因此，miR-382 可以作为癌症患者的诊断和治疗标志物。
